- Home
- ROIV vs MASI Comparison
ROIV vs MASI Comparison
Compare ROIV & MASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- MASI
- Stock Information
- Founded
- ROIV 2014
- MASI 1989
- Country
- ROIV United Kingdom
- MASI United States
- Employees
- ROIV N/A
- MASI N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- MASI Medical/Dental Instruments
- Sector
- ROIV Health Care
- MASI Health Care
- Exchange
- ROIV Nasdaq
- MASI Nasdaq
- Market Cap
- ROIV 8.6B
- MASI 8.1B
- IPO Year
- ROIV N/A
- MASI 2007
- Fundamental
- Price
- ROIV $15.09
- MASI $143.00
- Analyst Decision
- ROIV Strong Buy
- MASI Buy
- Analyst Count
- ROIV 9
- MASI 6
- Target Price
- ROIV $19.94
- MASI $194.60
- AVG Volume (30 Days)
- ROIV 8.2M
- MASI 600.1K
- Earning Date
- ROIV 11-11-2025
- MASI 11-04-2025
- Dividend Yield
- ROIV N/A
- MASI N/A
- EPS Growth
- ROIV N/A
- MASI N/A
- EPS
- ROIV N/A
- MASI N/A
- Revenue
- ROIV $23,233,000.00
- MASI $2,153,800,000.00
- Revenue This Year
- ROIV N/A
- MASI N/A
- Revenue Next Year
- ROIV $248.22
- MASI $7.80
- P/E Ratio
- ROIV N/A
- MASI N/A
- Revenue Growth
- ROIV N/A
- MASI 25.86
- 52 Week Low
- ROIV $8.73
- MASI $111.03
- 52 Week High
- ROIV $16.05
- MASI $194.88
- Technical
- Relative Strength Index (RSI)
- ROIV 78.02
- MASI 44.28
- Support Level
- ROIV $13.81
- MASI $140.11
- Resistance Level
- ROIV $16.05
- MASI $148.95
- Average True Range (ATR)
- ROIV 0.50
- MASI 4.05
- MACD
- ROIV 0.22
- MASI 0.34
- Stochastic Oscillator
- ROIV 77.14
- MASI 52.43
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About MASI Masimo Corporation
Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.